A 35-year-old white man with no prior illness presented with a 10-day history of colicky abdominal pain worsened with meals, and back pain. This was followed in 3 days by an asymptomatic purpuric ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...

Mission Statement: Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research ...